Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, South Carolina 29203, USA.
Am J Hematol. 2011 Jan;86(1):82-4. doi: 10.1002/ajh.21873. Epub 2010 Oct 14.
In a cohort of 2,194 children with sickle cell disease (SCD) treated in community-based services, we explored the types of medications used to treat vaso-occlusive (VOC) pain episodes, and the relative effectiveness of nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and adjunctive antidepressants or anticonvulsant medications on reducing acute VOC pain visits over time. Pharmacologic treatments for VOC pain consisted mainly of NSAIDs and weak opioids. Significantly more patients with more than 3 inpatient or ER VOC pain visits during their first year of SCD treatment were prescribed stronger opioids, SSRIs, SNRI/heterocyclics, and anticonvulsants. Prescription of both stronger opioids and SSRI antidepressants or anticonvulsants was significantly associated with lower cumulative rates of acute VOC pain visits over time. Using an observational study design and existing clinical data, these findings are intended to illustrate the potential clinical advantages of combining adjunctive antidepressants or anticonvulsants with primary pain medications for relief of acute VOC pain over time.
在一项针对 2194 名镰状细胞病(SCD)患儿的队列研究中,我们探讨了用于治疗血管阻塞性(VOC)疼痛发作的药物类型,以及非甾体抗炎药(NSAIDs)、阿片类药物和辅助抗抑郁药或抗惊厥药物在减轻急性 VOC 疼痛就诊次数方面的相对有效性。用于治疗 VOC 疼痛的药物治疗主要包括 NSAIDs 和弱阿片类药物。在 SCD 治疗的第一年,有更多的患者出现超过 3 次住院或急诊室 VOC 疼痛就诊,他们被开了更强效的阿片类药物、SSRIs、SNRI/杂环类和抗惊厥药物。开处方使用更强效的阿片类药物和 SSRI 抗抑郁药或抗惊厥药物与随着时间的推移,急性 VOC 疼痛就诊次数的累计率降低显著相关。通过观察性研究设计和现有的临床数据,这些发现旨在说明在缓解急性 VOC 疼痛方面,将辅助抗抑郁药或抗惊厥药物与主要止痛药物联合使用的潜在临床优势。